In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer

被引:48
作者
Chien, M
Astumian, M
Liebowitz, D
Rinker-Schaeffer, C
Stadler, WM
机构
[1] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA
[2] Univ Chicago, Urol Sect, Chicago, IL 60637 USA
关键词
cyclin-dependent kinase; cytotoxicity; apoptosis; multidrug resistance;
D O I
10.1007/s002800050948
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the in vitro effects of flavopiridol on bladder cancer cell lines, immortalized urothelial cell lines, and normal urothelial cells well characterized for defects in p53, pRb, and p16. Methods: Growth inhibition was assessed via an MTT assay and apoptosis via DAPI nuclear staining. Cell cycle analysis was performed via propidium iodide staining and fluorescent activated cell sorting (FACS). Multidrug-resistant cells were generated by continuous exposure to doxorubicin. Results: Growth inhibition was not correlated with inactivation of p53, pRb, or p16. All cells experienced G2/M arrest within 24 h of flavopiridol exposure. Modest apoptosis was observed but required 72 h of continuous drug exposure to become evident. There was no obvious synergistic or antagonistic toxicity when flavopiridol was combined with radiotherapy or cisplatin dosed at the IC50 despite the observation that radiotherapy and flavopiridol led to more profound G2/M arrest than either agent alone. Doxorubicin-resistant cells, demonstrated to overexpress the MDR1 multidrug-resistance protein were equally as sensitive to flavopiridol as the parental cells. Conclusions: Flavopiridol is a novel cell cycle inhibitor that may be a useful agent in bladder cancers with tumor suppressor gene alterations and/or multidrug resistance.
引用
收藏
页码:81 / 87
页数:7
相关论文
共 22 条
  • [12] OConnor PM, 1997, CANCER RES, V57, P4285
  • [13] Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
    Parker, BW
    Kaur, G
    Nieves-Neira, W
    Taimi, M
    Kohlhagen, G
    Shimizu, T
    Losiewicz, MD
    Pommier, Y
    Sausville, EA
    Senderowicz, AM
    [J]. BLOOD, 1998, 91 (02) : 458 - 465
  • [14] GROWTH-KINETICS AND DIFFERENTIATION INVITRO OF NORMAL HUMAN UROEPITHELIAL CELLS ON COLLAGEN GEL SUBSTRATES IN DEFINED MEDIUM
    REZNIKOFF, CA
    LORETZ, LJ
    PESCIOTTA, DM
    OBERLEY, TD
    IGNJATOVIC, MM
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1987, 131 (03) : 285 - 301
  • [15] LONG-TERM GENOME STABILITY AND MINIMAL GENOTYPIC AND PHENOTYPIC ALTERATIONS IN HPV16 E7-, BUT NOT E6-, IMMORTALIZED HUMAN UROEPITHELIAL CELLS
    REZNIKOFF, CA
    BELAIR, C
    SAVELIEVA, E
    ZHAI, Y
    PFEIFER, K
    YEAGER, T
    THOMPSON, KJ
    DEVRIES, S
    BINDLEY, C
    NEWTON, MA
    SEKHON, G
    WALDMAN, F
    [J]. GENES & DEVELOPMENT, 1994, 8 (18) : 2227 - 2240
  • [16] HUMAN BLADDER-CARCINOMA CELL-LINES AS INDICATORS OF ONCOGENIC CHANGE RELEVANT TO UROTHELIAL NEOPLASTIC PROGRESSION
    RIEGER, KM
    LITTLE, AR
    SWART, JM
    KASTRINAKIS, WV
    FITZGERALD, JM
    HESS, DT
    LIBERTINO, JA
    SUMMERHAYES, IC
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (03) : 683 - 690
  • [17] BINDING-PROPERTIES OF MONOCLONAL-ANTIBODIES RECOGNIZING EXTERNAL EPITOPES OF THE HUMAN MDR1 P-GLYCOPROTEIN
    SCHINKEL, AH
    ARCECI, RJ
    SMIT, JJM
    WAGENAAR, E
    BAAS, F
    DOLLE, M
    TSURUO, T
    MECHETNER, EB
    RONINSON, IB
    BORST, P
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (03) : 478 - 484
  • [18] Schwartz GK, 1997, CLIN CANCER RES, V3, P1467
  • [19] Cancer cell cycles
    Sherr, CJ
    [J]. SCIENCE, 1996, 274 (5293) : 1672 - 1677
  • [20] The 9p21 region in bladder cancer cell lines: Large homozygous deletions inactivate the CDKN2, CDKN2B and MTAP genes
    Stadler, WM
    Olopade, OI
    [J]. UROLOGICAL RESEARCH, 1996, 24 (04): : 239 - 244